Watchlist

Watchlist
Amgen Inc. (AMGN)
'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets
Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y…
Mining For ASCO 2018's Gold, Part 1: Early Breast Cancer Has Some Sheen
The 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO 2018) is upon us, and it's about as close to Christmas as I get in my line of work. There's so much data presented here, with thousands of abstracts delivered to an audience of some 30,000 healthcare professionals, that…
Amgen to collaborate on patient-centric cancer management initiative
Amgen (NASDAQ: AMGN ), together with the National Cancer Institute, the Federal Communications Commission Connect2Health Task Force, the University of Kentucky Markey Cancer Center and the University of California, San Diego Design Lab, have signed on participate in an initiative to help c…
Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment
THOUSAND OAKS, Calif. , May 23, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced a groundbreaking collaboration with the National Cancer Institute (NCI), the Federal Communications Commission (FCC) Connect2Health Task Force, the University of Kentucky (UK) Markey Cancer Cen…
Your Daily Pharma Scoop: Sesen Bio Presents Vicinium Data, UroGen's Mitogel Data, FibroGen In IPF
Analysis focus: SESN Sesen Bio (SESN) is a nanocap that has managed to get a drug through a phase 3 study. Not only that, but it has managed to come up with positive data for its lead antibody-drug conjugate (ADC) Vicinium in patients with high-grade non-muscle invasive bladder cancer (NMI…
Amgen Announces Voting Results Of Annual Meeting Of Stockholders
THOUSAND OAKS, Calif. , May 22, 2018 /PRNewswire/ --Amgen (NASDAQ: AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village , Calif.Approximately90 percent of outstanding shares were represented at the meeting. …
Entera Bio Re-Enters IPO Process
Quick Take Entera Bio ( ENTX ) has filed an amended F-1/A registration statement and now intends to sell units consisting of stock and warrants. The company is developing a pipeline of treatments for hypoparathyroidism and osteoporosis. ENTX management appears to be sweetening previo…
FDA OKs new indication for Amgen's Prolia
The FDA approves the use of Amgen's (NASDAQ: AMGN ) Prolia (denosumab) to treat glucocorticoid-induced osteoporosis in men and women at high risk of fracture, the fourth indication for the RANK ligand inhibitor. More news on: Amgen Inc., Healthcare stocks news, Read more …
FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis
THOUSAND OAKS, Calif. , May 21, 2018 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announcedthat the U.S. Food and Drug Administration (FDA) has approved the use ofProlia (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at h…
Amgen (AMGN) On Aimovig(TM), A New Innovation In Migraine - Slideshow
The following slide deck was published by Amgen Inc. in conjunction with this Read more …